Search

Your search keyword '"Montalban A"' showing total 8,947 results
Start Over Author "Montalban A"
8,947 results on '"Montalban A"'

201. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

Author

DiNardo, Courtney D., Venugopal, Sangeetha, Lachowiez, Curtis, Takahashi, Koichi, Loghavi, Sanam, Montalban-Bravo, Guillermo, Wang, Xuemei, Carraway, Hetty, Sekeres, Mikkael, Sukkur, Ameenah, Hammond, Danielle, Chien, Kelly, Maiti, Abhishek, Masarova, Lucia, Sasaki, Koji, Alvarado, Yesid, Kadia, Tapan, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop M., Patel, Bhumika, Dezern, Amy, Roboz, Gail, and Garcia-Manero, Guillermo

Published
2023
Full Text
View/download PDF

202. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Senapati, Jayastu, Jain, Nitin, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Pemmaraju, Naveen, Wierda, William, Garcia-Manero, Guillermo, Montalban Bravo, Guillermo, Sasaki, Koji, Kadia, Tapan M, Khoury, Joseph, Wang, Sa A, Haddad, Fadi G, Jacob, Jovitta, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2023
Full Text
View/download PDF

203. Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)

Author

Renom, Marta, Galán, Ingrid, Vidal, Xavier, Aldevert, Mireia, Curto, Gemma, Feliu, Patricia, García, Itziar, Gonzalo, Lorena, Sibera, Xavier, Anglada, Elisenda, Meza, Roger, García, Montserrat, Najas, Víctor, Mongay-Ochoa, Neus, Arévalo, María Jesús, Vidal-Jordana, Ángela, Tintoré, Mar, Bascuñana, Helena, Montalban, Xavier, Terré, Rosa, and Sastre-Garriga, Jaume

Published
2023
Full Text
View/download PDF

205. The RECAPACITA project: Description of the clinical, neuropsychological and functional profile of a sample of people with severe mental disorder and legal capacity modification in Spain

Author

Marcó-García, Silvia, Guilera, Georgina, Ferrer-Quintero, Marta, Ochoa, Susana, Escuder-Romeva, Gemma, Martínez-Mondejar, Arantxa, Montalbán-Roca, Vanessa, del Cacho, Núria, Rubio-Abadal, Elena, Escanilla-Casal, Ana, Martínez-Zambrano, Francisco, Balsells-Mejía, Sol, and Huerta-Ramos, Elena

Published
2023
Full Text
View/download PDF

206. Associations of sNfL with clinico‐radiological measures in a large MS population

Author

Elias S. Sotirchos, Kathryn C. Fitzgerald, Carol M. Singh, Matthew D. Smith, Maria Reyes‐Mantilla, Carrie M. Hersh, Megan H. Hyland, Ryan Canissario, Sarah B. Simmons, Georgina Arrambide, Xavier Montalban, Manuel Comabella, Robert T. Naismith, Min Qiao, Lauren B. Krupp, Jacqueline A. Nicholas, Katja Akgün, Tjalf Ziemssen, Richard Rudick, Elizabeth Fisher, Robert A. Bermel, Ellen M. Mowry, and Peter A. Calabresi

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Objective Evaluation of serum neurofilament light chain (sNfL), measured using high‐throughput assays on widely accessible platforms in large, real‐world MS populations, is a critical step for sNfL to be utilized in clinical practice. Methods Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high‐throughput, scalable immunoassay. Results Elevated sNfL levels for age (sNfL‐E) were found in 1238 MS participants (17.8%). Factors associated with sNfL‐E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease‐modifying therapy was associated with lower odds of sNfL‐E. MS participants with sNfL‐E exhibited worse neurological function (patient‐reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short‐term rates of whole brain atrophy in sNfL‐E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL‐E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age‐normative sNfL Z‐scores as a continuous variable. Interpretation Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking.

Published
2023
Full Text
View/download PDF

207. Sparse Vector Coding for Short-Packet Transmission on Industrial Communications: Reference Architecture and Design Challenges

Author

Inigo Bilbao, Lorenzo Fanari, Eneko Iradier, Pablo Angueira, and Jon Montalban

Subjects
Channel coding, data communication, decoding, forward error correction, industrial communications, industrial wireless sensor networks, Electronics, TK7800-8360, Industrial engineering. Management engineering, T55.4-60.8
Abstract

Reliable, fast, and deterministic communications are fundamental for future industrial wireless systems. This goal requires multiple cooperating technologies that pertain to different areas of the communication arena. The weight of the waveform and coding technique choices are critical to match industrial use cases' reliability and latency requirements. Specifically, this article contributes to the field of channel coding in wireless fieldbus links. Classical block coding schemes were designed to maximize information bit rates without stringent latency requirements. Their performance in applications that use short messages degrades significantly. Recently, sparse vector coding (SVC) has been proposed as a coding approach suitable for short-packet communications with moderate complexity and low processing latency. This article presents a comprehensive analysis of SVC and a reference communication framework for its implementation on a wireless system. A set of simulations is also designed to establish the cross correlation between the different parameters involved in the code design. As a result, the coding matrix has been identified as a critical parameter that can improve coding performance. In addition, this article includes two new procedures for determining the matrix that could lead to a gain of up to 2 dB with respect to the current state of the art.

Published
2023
Full Text
View/download PDF

211. A machine learning approach to analyse ozone concentration in metropolitan area of Lima, Peru

Author

Natalí Carbo-Bustinza, Marisol Belmonte, Vasti Jimenez, Paula Montalban, Magiory Rivera, Fredi Gutiérrez Martínez, Mohamed Mehdi Hadi Mohamed, Alex Rubén Huamán De La Cruz, Kleyton da Costa, and Javier Linkolk López-Gonzales

Subjects
Medicine, Science
Abstract

Abstract The main objective of this study is to model the concentration of ozone in the winter season on air quality through machine learning algorithms, detecting its impact on population health. The study area involves four monitoring stations: Ate, San Borja, Santa Anita and Campo de Marte, all located in Metropolitan Lima during the years 2017, 2018 and 2019. Exploratory, correlational and predictive approaches are presented. The exploratory results showed that ATE is the station with the highest prevalence of ozone pollution. Likewise, in an hourly scale analysis, the pollution peaks were reported at 00:00 and 14:00. Finally, the machine learning models that showed the best predictive capacity for adjusting the ozone concentration were the linear regression and support vector machine.

Published
2022
Full Text
View/download PDF

212. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022

Author

Rodriguez, Berta Suarez, Herrador, Bernardo R. Guzman, Franco, Asuncion Diaz, Farinas, Maria Paz Sanchez-Seco, Valero, Julia del Amo, Llorente, Adrian Hugo Aginagalde, Agreda, Juan Pablo Alonso Perez de, Malonda, Rosa Carbo, Castrillejo, Daniel, Lopez, Maria Dolores Chirlaque, Chong, Eduardo Javier Chong, Balbuena, Sonia Fernandez, Garcia, Virtudes Gallardo, Garcia-Cenoz, Manuel, Hernandez, Laura Garcia, Montalban, Elisa Gil, Carril, Fernando Gonzalez, Cortijo, Teresa Gonzalez, Bueno, Susana Jimenez, Sanchez, Aurora Limia, Dopido, Juan Antonio Linares, Lorusso, Nicola, Martins, Mario Margolles, Ochoa, Eva Maria Martinez, Mateo, Ana Martinez, Pena, Jacobo Mendioroz, Anton, Ana Isabel Negredo, Barros, Maria Teresa Otero, Martinez, Maria del Carmen Pacheco, Jimenez, Pilar Peces, Martin, Oscar-Guillermo Perez, Perez, Ana Isabel Rivas, Garcia, Maria Sastre, Soria, Fernando Simon, and Moros, Maria Jose Sierra

Subjects
Human monkeypox -- Statistics -- Control, Epidemics -- Statistics -- Control -- United Kingdom, Health
Abstract

During May-June 2022, after an alert notification initiated by the United Kingdom (1,2), >4,500 monkeypox cases had been confirmed worldwide, mainly in the European region (3-6). Chains of transmission without [...]

Published
2022
Full Text
View/download PDF

213. Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test

Author

Jennifer S Graves, Marcin Elantkowski, Yan-Ping Zhang, Frank Dondelinger, Florian Lipsmeier, Corrado Bernasconi, Xavier Montalban, Luciana Midaglia, and Michael Lindemann

Subjects
Medicine
Abstract

BackgroundThe development of touchscreen-based assessments of upper extremity function could benefit people with multiple sclerosis (MS) by allowing convenient, quantitative assessment of their condition. The Pinching Test forms a part of the Floodlight smartphone app (F. Hoffmann-La Roche Ltd, Basel, Switzerland) for people with MS and was designed to capture upper extremity function. ObjectiveThis study aimed to evaluate the Pinching Test as a tool for remotely assessing upper extremity function in people with MS. MethodsUsing data from the 24-week, prospective feasibility study investigating the Floodlight Proof-of-Concept app for remotely assessing MS, we examined 13 pinching, 11 inertial measurement unit (IMU)–based, and 13 fatigability features of the Pinching Test. We assessed the test-retest reliability using intraclass correlation coefficients [second model, first type; ICC(2,1)], age- and sex-adjusted cross-sectional Spearman rank correlation, and known-groups validity (data aggregation: median [all features], SD [fatigability features]). ResultsWe evaluated data from 67 people with MS (mean Expanded Disability Status Scale [EDSS]: 2.4 [SD 1.4]) and 18 healthy controls. In this cohort of early MS, pinching features were reliable [ICC(2,1)=0.54-0.81]; correlated with standard clinical assessments, including the Nine-Hole Peg Test (9HPT) (|r|=0.26-0.54; 10/13 features), EDSS (|r|=0.25-0.36; 7/13 features), and the arm items of the 29-item Multiple Sclerosis Impact Scale (MSIS-29) (|r|=0.31-0.52; 7/13 features); and differentiated people with MS-Normal from people with MS-Abnormal (area under the curve: 0.68-0.78; 8/13 features). IMU-based features showed similar test-retest reliability [ICC(2,1)=0.47-0.84] but showed little correlations with standard clinical assessments. In contrast, fatigability features (SD aggregation) correlated with 9HPT time (|r|=0.26-0.61; 10/13 features), EDSS (|r|=0.26-0.41; 8/13 features), and MSIS-29 arm items (|r|=0.32-0.46; 7/13 features). ConclusionsThe Pinching Test provides a remote, objective, and granular assessment of upper extremity function in people with MS that can potentially complement standard clinical evaluation. Future studies will validate it in more advanced MS. Trial RegistrationClinicalTrials.gov NCT02952911; https://clinicaltrials.gov/study/NCT02952911

Published
2023
Full Text
View/download PDF

214. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Author

Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, and Xavier Montalban

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Background and objectives: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-year CARE-MS extension, during which alemtuzumab-treated participants (‘alemtuzumab-only’) could receive additional courses upon disease activity, and IFN-treated participants switched to alemtuzumab (‘IFN-alemtuzumab’). Participants who completed the CARE-MS extension could enroll in the open-label TOPAZ study which assessed safety and efficacy for 5–7 years (11–13 years after alemtuzumab/IFN initiation). Methods: Participants received additional alemtuzumab courses as needed. Assessments included adverse events (AEs; primary outcome), annualized relapse rate (ARR), 6-month confirmed disability worsening [CDW; ⩾1.0-point Expanded Disability Status Scale (EDSS) score increase or ⩾1.5 if baseline EDSS = 0], and 6-month confirmed disease improvement [CDI; >1.0-point EDSS decrease (baseline score ⩾2.0)]. Results: 43.5% of alemtuzumab-only participants from CARE-MS II and 54.2% from CARE-MS I received no additional alemtuzumab courses; 30.0% and 20.9%, respectively, received one additional course (the median). Incidences of AEs, including thyroid AEs and infections, declined over time. The safety profile of alemtuzumab was similar for participants who received zero, one, or two additional courses. For CARE-MS II participants, who had inadequate response to previous treatment, ARR remained low during Years 3–13 for the alemtuzumab-only [0.17; 95% confidence interval (CI) 0.15–0.20] and IFN-alemtuzumab (0.14; 0.11–0.17) groups. At Year 11, the proportions of participants who were either free from CDW or who had CDI were higher in the alemtuzumab-only group (58% and 49%, respectively) than in the IFN-alemtuzumab group (51% and 37%). For CARE-MS I participants, who were previously treatment-naïve, clinical outcomes remained improved, and no between-group differences were apparent. Conclusion: Safety risks associated with alemtuzumab treatment declined over time. Clinical benefits were maintained up to 11–13 years, and most participants did not require more than one additional course. Clinicaltrials.gov identifiers: NCT00530348; NCT00548405; NCT00930553; NCT02255656

Published
2023
Full Text
View/download PDF

215. P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Author

Fadi Haddad, Elias Jabbour, Marianne Zoghbi, Nicholas Short, Jayastu Senapati, Walid Macaron, Cedric Nasnas, Lewis Nasr, Naveen Pemmaraju, Nitin Jain, William G. Wierda, Gautam Borthakur, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Kelly Chien, Jennifer Thankachan, Rebecca Garris, and Hagop Kantarjian

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

216. P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY

Author

Nicholas Short, Walid Macaron, Courtney Dinardo, Naval Daver, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Ghayas Issa, Koji Sasaki, Jan Burger, Abhishek Maiti, Yesid Alvarado, Jennifer Thankachan, Regina Abramova, Lewis Nasr, Cedric Nasnas, Marianne Zoghbi, Tapan Kadia, Marina Konopleva, Hagop Kantarjian, and Farhad Ravandi

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

217. P729: LANDSCAPE OF GERMLINE PATHOGENIC/ LIKELY PATHOGENIC MUTATIONS INVOLVING DNA REPAIR GENES IN SOLID TUMOR PATIENTS WITH ANTECEDENT OR SUBSEQUENT MYELOID NEOPLASMS

Author

Kimberly Hein, Sinchita Roy Chowdhuri, Courtney Dinardo, Guillermo Garcia-Manero, Keyur Patel, Mark Routbort, Richard Yang, Beenu Thakral, Guillermo Montalban-Bravo, Sanam Loghavi, L. Jeffrey Medeiros, Kelly Chien, Rajyalakshmi Luthra, and Rashmi Kanagal-Shamanna

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

218. P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE

Author

Kelly Chien, Samuel Urrutia, Ziyi LI, Rashmi Kanagal-Shamanna, Emmanuel Almanza, Tareq Abuasab, Georgina Gener, Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Nicholas Short, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Danielle Hammond, Mahesh Swaminathan, Koji Sasaki, Sherry Pierce, Hagop Kantarjian, and Guillermo Garcia-Manero

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

219. S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

Author

Nicholas Short, Elias Jabbour, Nitin Jain, Xuelin Huang, Walid Macaron, Lewis Nasr, Guillermo Montalban-Bravo, Tapan Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Ghayas Issa, Fadi Haddad, Cedric Nasnas, Marianne Zoghbi, Rebecca Garris, Marina Konopleva, Farhad Ravandi, and Hagop Kantarjian

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

220. P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS

Author

Alexandre Bazinet, Naszrin Arani, Kelly Chien, Danielle Hammond, Tapan Kadia, Gautam Borthakur, Yesid Alvarado, Koji Sasaki, Courtney Dinardo, Naveen Pemmaraju, Lucia Masarova, Nicholas Short, Musa Yilmaz, Naval Daver, Elias Jabbour, Farhad Ravandi, Rashmi Kanagal-Shamanna, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, and Guillermo Montalban-Bravo

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

222. P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE

Author

Samuel Urrutia, Kelly Chien, Ziyi LI, Alex Bataller, Emmanuel Almanza, Koji Sasaki, Guillermo Montalban-Bravo, Nicholas Short, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos Bueso Ramos, Sherry Pierce, Hagop Kantarjian, and Guillermo Garcia-Manero

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

225. P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL

Author

Fadi Haddad, Elias Jabbour, Marianne Zoghbi, Nicholas Short, Cedric Nasnas, Lewis Nasr, Walid Macaron, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas Issa, Monica Kwari, Ricardo Delumpa, Ejiroghene Mayor, Wuliamatu Deen, Jennifer Thankachan, Christopher Loiselle, Juan Rivera, Anna Milton, Lourdes Waller, Glenda Banks, Rebecca Garris, Farhad Ravandi, and Hagop Kantarjian

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

226. P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND

Author

Daniel Nguyen, Hagop Kantarjian, Aram Bidikian, Courtney Dinardo, Tapan Kadia, Naval Daver, Gautam Borthakur, Elias Jabbour, Musa Yilmaz, Nicholas Short, Abhishek Maiti, Koji Sasaki, Guillermo Montalban-Bravo, Danielle Hammond, Sherry Pierce, Michael Andreeff, Guillermo Garcia-Manero, Farhad Ravandi, and Ghayas Issa

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

227. P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA

Author

Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi LI, Danielle Hammond, Kelly Chien, Juan Jose Rodriguez-Sevilla, Koji Sasaki, Elias Jabbour, Courtney Dinardo, Koichi Takahashi, Nicholas Short, Ghayas Issa, Tapan Kadia, Naveen Pemmaraju, Farhad Ravandi, Naval Daver, Gautam Borthakur, Sanam Loghavi, Sherry Pierce, Carlos Bueso Ramos, and Guillermo Garcia-Manero

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

228. P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX

Author

Alexandre Bazinet, Sai Prasad Desikan, Ziyi LI, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Bailey Mirabella, Stephany Hendrickson, Liz Romero, Simona Colla, Irene Ganan-Gomez, Juan Jose Rodriguez-Sevilla, Tapan Kadia, Courtney Dinardo, Naval Daver, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, and Guillermo Garcia-Manero

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

229. S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA

Author

Alex Bataller, Alexandre Bazinet, Sangeetha Venugopal, Guillermo Montalban-Bravo, Yesid Alvarado, Kelly Chien, Ghayas Issa, Nicholas Short, Danielle Hammond, Lucia Masarova, Tapan Kadia, Rashmi Kanagal-Shamanna, Stephany Hendrickson, Farhad Ravandi, Elias Jabbour, Hagop Kantarjian, and Guillermo Garcia-Manero

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

242. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Jain, Nitin, Huang, Xuelin, Montalban-Bravo, Guillermo, Banerjee, Pinaki, Rezvani, Katayoun, Jiang, Xianli, Kim, Kun Hee, Kanagal-Shamanna, Rashmi, Khoury, Joseph D, Patel, Keyur, Kadia, Tapan M, Daver, Naval, Chien, Kelly, Alvarado, Yesid, Garcia-Manero, Guillermo, Issa, Ghayas C, Haddad, Fadi G, Kwari, Monica, Thankachan, Jennifer, Delumpa, Ricardo, Macaron, Walid, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2023
Full Text
View/download PDF

243. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

Author

Coll, Llucia, Pareto, Deborah, Carbonell-Mirabent, Pere, Cobo-Calvo, Álvaro, Arrambide, Georgina, Vidal-Jordana, Ángela, Comabella, Manuel, Castilló, Joaquín, Rodríguez-Acevedo, Breogán, Zabalza, Ana, Galán, Ingrid, Midaglia, Luciana, Nos, Carlos, Salerno, Annalaura, Auger, Cristina, Alberich, Manel, Río, Jordi, Sastre-Garriga, Jaume, Oliver, Arnau, Montalban, Xavier, Rovira, Àlex, Tintoré, Mar, Lladó, Xavier, and Tur, Carmen

Published
2023
Full Text
View/download PDF

244. Multiple sclerosis progression: time for a new mechanism-driven framework

Author

Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Chataway, Jeremy, Chitnis, Tanuja, Comi, Giancarlo, Derfuss, Tobias, Finlayson, Marcia, Goldman, Myla, Green, Ari, Hellwig, Kerstin, Kos, Daphne, Miller, Aaron, Mowry, Ellen, Oh, Jiwon, Salter, Amber, Sormani, Maria Pia, Tintore, Mar, Tremlett, Helen, Trojano, Maria, van der Walt, Anneke, Vukusic, Sandra, Waubant, Emmaunelle, Kuhlmann, Tanja, Moccia, Marcello, Coetzee, Timothy, Cohen, Jeffrey A, Correale, Jorge, Graves, Jennifer, Marrie, Ruth Ann, Montalban, Xavier, Yong, V Wee, Thompson, Alan J, and Reich, Daniel S

Published
2023
Full Text
View/download PDF

245. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

Author

Yang, Hui, Garcia-Manero, Guillermo, Sasaki, Koji, Montalban-Bravo, Guillermo, Tang, Zhenya, Wei, Yue, Kadia, Tapan, Chien, Kelly, Rush, Diana, Nguyen, Ha, Kalia, Awdesh, Nimmakayalu, Manjunath, Bueso-Ramos, Carlos, Kantarjian, Hagop, Medeiros, L. Jeffrey, Luthra, Rajyalakshmi, and Kanagal-Shamanna, Rashmi

Published
2022
Full Text
View/download PDF

246. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes

Author

Sakhdari, Ali, Class, Caleb, Montalban-Bravo, Guillermo, Sasaki, Koji, Bueso-Ramos, Carlos E., Patel, Keyur P., Routbort, Mark J., Loghavi, Sanam, Ok, Chi Young, Quesada, Andres, Khoury, Joseph D., Konoplev, Sergej N., Kantarjian, Hagop P., Garcia-Manero, Guillermo, Medeiros, L. Jeffrey, and Kanagal-Shamanna, Rashmi

Published
2022
Full Text
View/download PDF

248. Asteroseismology of evolved stars to constrain the internal transport of angular momentum. I. Efficiency of transport during the subgiant phase

Author

Eggenberger, P., Deheuvels, S., Miglio, A., Ekström, S., Georgy, C., Meynet, G., Lagarde, N., Salmon, S., Buldgen, G., Montalbán, J., Spada, F., and Ballot, J.

Subjects
Astrophysics - Solar and Stellar Astrophysics
Abstract

Context: The observations of solar-like oscillations in evolved stars have brought important constraints on their internal rotation rates. To correctly reproduce these data, an efficient transport mechanism is needed in addition to meridional circulation and shear instability. Aims: We study the efficiency of the transport of angular momentum during the subgiant phase. Results: The precise asteroseismic measurements of both core and surface rotation rates available for the six Kepler targets enable a precise determination of the efficiency of the transport of angular momentum needed for each of these subgiants. These results are found to be insensitive to all the uncertainties related to the modelling of rotational effects before the post-main sequence phase. An interesting exception in this context is the case of young subgiants (typical values of log(g) close to 4), because their rotational properties are sensitive to the degree of radial differential rotation on the main sequence. These young subgiants constitute therefore perfect targets to constrain the transport of angular momentum on the main sequence from asteroseismic observations of evolved stars. As for red giants, we find that the efficiency of the additional transport process increases with the mass of the star during the subgiant phase. However, the efficiency of this undetermined mechanism decreases with evolution during the subgiant phase, contrary to what is found for red giants. Consequently, a transport process with an efficiency that increases with the degree of radial differential rotation cannot account for the core rotation rates of subgiants, while it correctly reproduces the rotation rates of red giant stars. This suggests that the physical nature of the additional mechanism needed for the internal transport of angular momentum may be different in subgiant and red giant stars., Comment: 10 pages, 11 figures, accepted for publication in A&A

Published
2018
Full Text
View/download PDF

249. The mass in terms of Einstein and Newton

Author

de Lima, Levi Lopes, Girão, Frederico, and Montalbán, Amilcar

Subjects
Mathematics - Differential Geometry, General Relativity and Quantum Cosmology
Abstract

It is shown that the mass of an asymptotically flat manifold with a noncompact boundary can be computed in terms of limiting surface integrals involving the Einstein tensor of the interior metric and the Newton tensor attached to the second fundamental form of the boundary. This extends to this setting previous results by several authors in the boundaryless case. The method outlined below, which is based on a coordinate-free approach due to Herzlich, also applies to asymptotically hyperbolic manifolds, again with a noncompact boundary, for which a similar notion of mass has been recently considered by Almaraz and the first named author, and both cases will be discussed here., Comment: 11 pages; no figures

Published
2018
Full Text
View/download PDF

250. Calibration of the mixing-length parameter $\alpha$ for the MLT and FST models by matching with CO$^5$BOLD models

Author

Sonoi, T., Ludwig, H. -G., Dupret, M. -A., Montalbán, J., Samadi, R., Belkacem, K., Caffau, E., and Goupil, M. -J.

Subjects
Astrophysics - Solar and Stellar Astrophysics
Abstract

The CoRoT and Kepler missions provided a wealth of high-quality data for solar-like oscillations. To make the best of such data for seismic inferences, we need theoretical models with precise near-surface structure, which has significant influence on solar-like oscillation frequencies. The mixing-length parameter, $\alpha$, is a key factor for the near-surface structure. In the convection formulations used in evolution codes, the $\alpha$ is a free parameter that needs to be properly specified. We calibrated $\alpha$ values by matching entropy profiles of 1D envelope models with those of 3D CO$^5$BOLD models. For such calibration, previous works concentrated on the classical mixing-length theory (MLT). Here we also analyzed the full spectrum turbulence (FST) models. For the atmosphere part in the 1D models, we use the Eddington grey $T(\tau)$ relation and the one with the solar-calibrated Hopf-like function. For both the MLT and FST models with a mixing length $l=\alpha H_p$, calibrated $\alpha$ values increase with increasing $g$ or decreasing $T_{\rm eff}$. For the FST models, we also calibrated values of $\alpha^*$ defined as $l=r_{\rm top}-r+\alpha^*H_{p,{\rm top}}$. $\alpha^*$ is found to increase with $T_{\rm eff}$ and $g$. As for the correspondence to the 3D models, the solar Hopf-like function gives a photospheric-minimum entropy closer to a 3D model than the Eddington $T(\tau)$. The structure below the photosphere depends on the convection model. However, not a single convection model gives the best correspondence since the averaged 3D quantities are not necessarily related via an EOS. Although the FST models with $l=r_{\rm top}-r+\alpha^*H_{p,{\rm top}}$ are found to give the frequencies closest to the solar observed ones, a more appropriate treatment of the top part of the 1D convective envelope is necessary., Comment: 14 pages, 18 figures, accepted to Astronomy and Astrophysics

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results